BioSpace News Archive

Medical care robots are the combination of medication and innovation. These robots help specialists in doing medical procedures with practically wonderful exactness.

Adocia announced that Gerard Soula, Adocia’s CEO, will be presenting at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place from September 13 to 15, 2021.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced the grant of an inducement award outside of the Company’s 2019 Stock Incentive Plan to Mel Hayes, the Company’s newly appointed Chief Commercial Officer.

Senhwa Biosciences, Inc. announced that their first patient has been successfully dosed, in a Phase 1b clinical study of Pidnarulex as a potential treatment for solid tumors with Homologous Recombination (HR) gene mutations.

- Strong Balance Sheet to Fund Pipeline of Omega Epigenomic Controllers™ with $122.4 Million in Cash and Cash Equivelents as of June 30, 2021 and additional $141.1 Million in Gross Proceeds from the Initial Public Offering in the Third Quarter 2021

Precision BioSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Monte Rosa Therapeutics, Inc., a biotechnology company developing novel molecular glue precision medicines, announced that it will be added to the Russell 2000® and Russell 3000® Indexes as part of second quarter initial public offering additions, effective Sept. 20, 2021.

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Robert Barrow, Chief Executive Officer of MindMed, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021

Amolyt Pharmatoday announced that it will host a key opinion leader (KOL) webinar on AZP-3601, the Company’s lead product candidate for the potential treatment of hypoparathyroidism, on Friday, October 1, 2021 at 10:00 am ET.

BioCardia®, Inc. today announces data from its CardiAMP® Cell Therapy Heart Failure pivotal trial (ClinicalTrials.gov Identifier: NCT02438306), which are being presented at the Heart Failure Society of America Annual Meeting 2021 on Saturday, September 11.